These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4522 related articles for article (PubMed ID: 6321412)

  • 1. A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation.
    Kinsella TJ; Russo A; Mitchell JB; Rowland J; Jenkins J; Schwade J; Myers CE; Collins JM; Speyer J; Kornblith P
    Int J Radiat Oncol Biol Phys; 1984 Jan; 10(1):69-76. PubMed ID: 6321412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous intravenous infusions of bromodeoxyuridine as a clinical radiosensitizer.
    Kinsella TJ; Mitchell JB; Russo A; Aiken M; Morstyn G; Hsu SM; Rowland J; Glatstein E
    J Clin Oncol; 1984 Oct; 2(10):1144-50. PubMed ID: 6092551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitization of hematopoietic precursor cells (CFUc) in glioblastoma patients receiving intermittent intravenous infusions of bromodeoxyuridine (BUdR).
    Mitchell JB; Kinsella TJ; Russo A; McPherson S; Rowland J; Smith BH; Kornblith PL; Glatstein E
    Int J Radiat Oncol Biol Phys; 1983 Apr; 9(4):457-63. PubMed ID: 6303991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas.
    Hegarty TJ; Thornton AF; Diaz RF; Chandler WF; Ensminger WD; Junck L; Page MA; Gebarski SS; Hood TW; Stetson PL
    Int J Radiat Oncol Biol Phys; 1990 Aug; 19(2):421-8. PubMed ID: 2168357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial of intravenous infusion of bromodeoxyuridine (BUdR) for radiosensitization of malignant brain tumors.
    Matsutani M; Kohno T; Nagashima T; Nagayama I; Matsuda T; Hoshino T; Sano K
    Radiat Med; 1988; 6(1):33-9. PubMed ID: 3045898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors.
    Phuphanich S; Levin EM; Levin VA
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1769-72. PubMed ID: 6480461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromodeoxyuridine alternating with radiation for advanced uterine cervix cancer: a phase I and drug incorporation study.
    Eisbruch A; Robertson JM; Johnston CM; Tworek J; Reynolds KR; Roberts JA; Lawrence TS
    J Clin Oncol; 1999 Jan; 17(1):31-40. PubMed ID: 10458215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-arterial bromodeoxyuridine radiosensitization and radiation in treatment of malignant astrocytomas.
    Greenberg HS; Chandler WF; Diaz RF; Ensminger WD; Junck L; Page MA; Gebarski SS; McKeever P; Hood TW; Stetson PL
    J Neurosurg; 1988 Oct; 69(4):500-5. PubMed ID: 3047341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
    Prados MD; Seiferheld W; Sandler HM; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1147-52. PubMed ID: 15001257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer.
    Kinsella TJ; Russo A; Mitchell JB; Collins JM; Rowland J; Wright D; Glatstein E
    Int J Radiat Oncol Biol Phys; 1985 Nov; 11(11):1941-6. PubMed ID: 2997090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study.
    Phillips TL; Levin VA; Ahn DK; Gutin PH; Davis RL; Wilson CB; Prados MD; Wara WM; Flam MS
    Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):709-14. PubMed ID: 1651306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers.
    Kinsella TJ; Mitchell JB; Russo A; Morstyn G; Glatstein E
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1399-406. PubMed ID: 6381432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme.
    Jackson D; Kinsella T; Rowland J; Wright D; Katz D; Main D; Collins J; Kornblith P; Glatstein E
    Am J Clin Oncol; 1987 Oct; 10(5):437-43. PubMed ID: 2821790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitization with carotid intra-arterial bromodeoxyuridine +/- 5-fluorouracil biomodulation for malignant gliomas.
    Greenberg HS; Chandler WF; Ensminger WD; Sandler H; Junck L; Page MA; Crane D; McKeever P; Tankanow R; Bromberg J
    Neurology; 1994 Sep; 44(9):1715-20. PubMed ID: 7936303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-arterial 5-bromo-2-deoxyuridine (BUdR) radiosensitization with external beam radiation in rhesus monkeys: toxicity study.
    Greenberg HS; Chandler WF; Diaz RF; Averill DR; Gebarski SS; Lichter AS; Ensminger WD
    J Neurooncol; 1988 Dec; 6(4):349-54. PubMed ID: 3221261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
    Groves MD; Maor MH; Meyers C; Kyritsis AP; Jaeckle KA; Yung WK; Sawaya RE; Hess K; Bruner JM; Peterson P; Levin VA
    Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):127-35. PubMed ID: 10477016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of bromodeoxyuridine in malignant and normal cells following therapy: relationship to complications.
    Morstyn G; Kinsella T; Hsu SM; Russo A; Gratzner H; Mitchell J
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1441-5. PubMed ID: 6469767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.
    Prados MD; Scott C; Sandler H; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
    Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1109-15. PubMed ID: 10613302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs.
    Wollner IS; Knutsen CA; Ullrich KA; Chrisp CE; Juni JE; Andrews JC; Tuscan MJ; Stetson PL; Ensminger WD
    Cancer Res; 1987 Jun; 47(12):3285-90. PubMed ID: 3581069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined radiosensitizer infusion and irradiation of osteogenic sarcomas.
    Goffinet DR; Kaplan HS; Donaldson SS; Bagshaw MA; Wilbur JR
    Radiology; 1975 Oct; 117(1):211-4. PubMed ID: 1080572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 227.